Shuguang Fang

Wecare Probiotic Research and Development Center (WPC) Wecare Probiotics Co., Ltd Suzhou China

Health Outcomes Studied

• Improved Gut Microbiota Composition
• Increased Adiponectin Levels
• Increased Fecal Butyrate Levels
• Increased Intestinal GLP-1 Levels
• Reduced Diarrhea Rate
• Reduced Tumor Necrosis Factor Alpha
• Reduced Uric Acid Levels

Papers (7)

• 2026
  Weizmannia coagulans BC99 improved intestinal motility and chronic constipation through regulating gut microbiota: a randomized, double-blind, placebo-controlled trial.10.1007/s00394-026-03953-5
• 2026
  Bifidobacterium Breve BBr60 Improves Obesity Via the Gut Microbiota-Short-Chain Fatty Acid-IL-27/GLP-1 Axis: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial.10.1007/s12602-025-10885-9
• 2026
  Weizmannia coagulans BC99 alleviates alcohol-induced oxidative stress and gut barrier dysfunction via modulation of butyrate metabolism: A randomized, double-blind, placebo-controlled trial.10.1016/j.freeradbiomed.2026.02.032
• 2026Primary author
  Clinical Safety and Tolerability of <i>Bifidobacterium bifidum</i> BBi32: An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial With Genomic and In Vitro Corroboration.10.1002/fsn3.71420
• 2026
  Gut microbiota and immune regulation by Lactobacillus delbrueckii subsp. bulgaricus LB42: From preclinical safety assessment to clinical evidence.10.1016/j.fct.2025.115851
• 2026
  Multi-Strain Probiotics BLa80, LRa05, and BBr60 Modulate Inflammation, Bile Acids, and Gut Microbiota in Type 2 Diabetes: A Randomized Controlled Trial.10.1002/fsn3.71735
• 2025
  Efficacy and Safety of <i>Lactobacillus acidophilus</i> LA85 in Preventing Antibiotic-Associated Diarrhea: A Randomized, Placebo-Controlled Study.10.1002/fsn3.70490